Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repurposed immunomodulatory drugs for pre-ICU hospitalized COVID-19 patients
ISRCTN11188345Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- May 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Baricitinib + standard of care, Ravulizumab + standard of care and Standard of care (3 arms). Primary endpoint: Primary composite endpoint. Started May 2020; status: completed.
02
Drugs
baricitinibravulizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN11188345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11188345.